RxDoctor Payments DataLook up a doctor →

Omar Cabahug, MD

Neurology · Henderson, NVNPI 1891895488

Payments from drug & device makers

$7,343in general payments, 2019–2025

Across 420 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$503
  • Lundbeck LLC$450
  • Pfizer$406
  • Acadia Pharmaceuticals Inc$377
  • Bristol Myers Squibb$296
  • plus $3K from 44 others

What the payments were for

  • Speaking & faculty fees$190%
  • Food & beverage$7,324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,343 in reported general payments places this provider in the 65th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$1,329,353
Medicare patients
1,063
Services billed
37,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-50102$1,879,115
OctagamImmun Globg(Igg)/Malt/Iga Ov5011$360,038
GammakedImmune Globul G/Gly/Iga Avg 4614$208,410
CopaxoneGlatiramer Acetate23$133,147
NuplazidPimavanserin Tartrate14$78,821
Dimethyl Fumarate14$55,892
UbrelvyUbrogepant41$45,172
Nurtec OdtRimegepant Sulfate22$34,472
NeuproRotigotine25$32,517
BotoxOnabotulinumtoxina22$26,102
QuliptaAtogepant14$26,058
Aimovig AutoinjectorErenumab-Aooe16$21,778
NamzaricMemantine Hcl/Donepezil Hcl12$16,823
Memantine Hcl366$14,084
Rivastigmine47$12,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$85$1,879,115102 claims
PfizerOctagam, Nurtec Odt$406$394,50933 claims
Teva Pharmaceuticals USA, Inc.Copaxone$95$133,14723 claims
AbbVieUbrelvy, Botox, Qulipta, Namzaric$2,211$114,15489 claims
Acadia Pharmaceuticals IncNuplazid$377$78,82114 claims
UCB, Inc.Neupro$150$32,51725 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$31$2,105117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 145 neurology providers in Nevada.

Other neurology in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →